Peripheral Nerve Injury Upper LimbPhase 3NCT06616025
This Study Will Evaluate the Effectiveness of NTX-001, a Surgical Nerve Repair Product When Used in People With Upper Extremity Nerve Lacerations.
A Phase 3 study testing NTX-001 (PEG-Fusion) in people with Peripheral Nerve Injury Upper Limb and Peripheral Nerve Injury (PNI), run by Neuraptive Therapeutics Inc. at 25 sites in United States.
Trial summary
NTX-001 is a single use surgical product intended for use in conjunction with standard suture neurorrhaphy of severed nerves in patients between 18 and 80. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Peripheral Nerve Injury Upper Limb, Peripheral Nerve Injury (PNI)
- What is being tested?
- NTX-001 (PEG-Fusion)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 98 participants
- Where
- 25 sitesUnited States
- Study dates
- 10 Feb 2025to 30 Apr 2027
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- The subject has voluntarily agreed to participate in this study and has signed an Institutional Review Board (IRB) approved informed consent form.
- The subject is between eighteen (18) and eighty (80) years of age.
- The subject has clinical evidence of a Sunderland's 4th degree (Class II) or 5th degree (Class III) nerve transection(s) that has resulted in upper extremity nerve impairment that requires surgical treatment.
Who cannot join
- Subjects whose nerve repair will occur greater than 48 hours after nerve transection.
- Subjects requiring nerve repair involving an autograft, allograft or conduit(s).
- Subjects with multiple transected nerve injuries are allowed into the study only if all injuries are amenable to direct repair.
- Subjects who, in the judgement of the investigator, are not likely to demonstrate meaningful recovery within a reasonable time frame during follow up due to significant muscle atrophy or other morbidity.
- The subject's injury is a result of a suicide attempt or self- harm.
- The subject has documented history or clinical signs of any condition where NTX-001 might not prove beneficial (e.g., systemic neuromuscular disease, systemic neurological deficit, or other treatments known to affect the growth and/or physiology of the neural and vascular system).
Show all 9Show fewer
- The subject has a known allergy to polyethylene glycol (PEG) or human grade silicone.
- The subject is pregnant or breastfeeding.
- The subject is currently enrolled in another investigational study or has participated in an investigational study within 30 days prior to screening.
Trial locations and contacts
25 sites in 1 country. Contact the study team or a site near you to ask about taking part.
25 sites in 1 country
United States25 sites, 25 recruiting
- Recruiting
Grady Health
Atlanta, Georgia, 30303
Nicole A Zelenski, MD, 404-251-1566, nicole.ann.zelenski@emory.edu
Morgan Fuller, MS, 404-251-8953, mrfulle@emory.edu
- Recruiting
Curtis National Center at MedStar Union Memorial Hospital
Baltimore, Maryland, 21218
Kenneth R Means Jr., MD, 410-554-2486, kennethrmeans@curtishand.com
Ike Fleming, Research Program Manager, 410-554-2486, Ike.C.Fleming@medstar.net
- Recruiting
The Cooper Health System
Camden, New Jersey, 08103
David A Fuller, MD, 856-968-7262, Fuller-David@CooperHealth.edu
Pietro M Gentile, Manager of Research Division, 856-213-0094, gentile-pietro@CooperHealth.edu
- Recruiting
Medical University of South Carolina
Charleston, South Carolina, 29429
Charles A Daly, MD, 843-876-2211, dalyc@musc.edu
Lisa Mock, 843-876-2211, mockl@musc.edu
- Recruiting
UVA Health
Charlottesville, Virginia, 22903
Brett DeGeorge, MD, 434-924-5078, bd6u@virginia.edu
Milos Lesevic, MD, 434-924-2549, ML4EC@uvahealth.org
- Recruiting
University of Chicago
Chicago, Illinois, 60637
Jeffrey Stepan, MD MSc, 773-702-0494, jstepan@bsd.uchicago.edu
Michael Koch, 773-834-0822, mkoch@bsd.uchicago.edu
- Recruiting
UC Health
Cincinnati, Ohio, 45267
Sonu Jain, MD, FACS, 513-558-2765, sonu.jain@uc.edu
Brittany Rowley, CCRC Clinical Research Professional III, 513-558-2765, rowleybm@ucmail.uc.edu
- Recruiting
University of Cincinnati Health
Cincinnati, Ohio, 45267
Sonu Jain, MD, 504-296-8215, jain3su@ucmail.uc.edu
Brittany Rowley, Lead Coordinator, 513-558-2765, rowleybm@ucmail.uc.edu
- Recruiting
The MetroHealth System
Cleveland, Ohio, 44109
Kyle J Chepla, MD, 216-778-7878, kchepla@metrohealth.org
Hannah Amiott, Clinical Research Coordinator, 216-778-1163, HAmiott@metrohealth.org
- Recruiting
Missouri Orthopaedic Institute
Columbia, Missouri, 65211
Julia Nuelle, MD, 573-882-2663, julia.nuelle@health.missouri.edu
Bryce Fletcher, 573-884-1248, brycefletcher@health.missouri.edu
- Recruiting
The Ohio State University Wexner Medical Center
Columbus, Ohio, 43212
Ryan Schmucker, MD, 614-293-8566, Ryan.Schmucker@osumc.edu
Emily Rice, 614-293-5871, Emily.Rice2@osumc.edu
- Recruiting
Baylor, Scott and White Health
Dallas, Texas, 75246
Asadullah Helal, MD, 469-800-7200, Asadullah.Helal@BSWHealth.org
Angela Young Young - Clinical Research Coordinator, 214-820-4787, Angela.Young1@BSWHealth.org
- Not yet recruiting
Cedars Sinai Medical Center
Los Angeles, California, 90048
Meghan C McCullough, MD, 703-371-9220, Meghan.McCullough@cshs.org
Michael Fernandez, Clinical Research Coordinator, 310-423-0201, Michael.Fernandez2@cshs.org
- Recruiting
University of Louisville
Louisville, Kentucky, 40202
Tuna Ozyurekoglu, MD, 502-562-0352, tuna.ozyurekoglu@louisville.edu
Anne Jerde, Lead Coordinator, 502-852-5251, ann.jerde@louisville.edu
- Recruiting
Texas Tech
Lubbock, Texas, 79415
Brendan J MacKay, MD, 806-743-2584, brendan.j.mackay@ttuhsc.edu
Evan J Hernandez, Clinical Researcher - MBA, 806-743-6846, evan.j.hernandez@ttuhsc.edu
- Recruiting
Louisiana State University Health Sciences Center
New Orleans, Louisiana, 70112
Harvey Chim,, MD, (504) 568-4750, hchim@lsuhsc.edu
Tanja Milosavljevic, MSc, PhD, 504-568-6876, tmilos@lsuhsc.edu
- Recruiting
NYU Langone Health
New York, New York, 10003
Jacques Hacquebord, MD, 212-263-7582, Jacques.hacquebord@nyulangone.org
Anne Genzelev, 212-263-7582, Anne.Genzelev@nyulangone.org
- Recruiting
Rothman Orthopedics - Advent Health
Orlando, Florida, 32804
Amir Reza Kachooei, MD PhD, 844-407-4070, amir.kachooei@rothmanortho.com
Rosemary Vargas, Coordinator, 407-752-5452, Rosemary.Vargas@AdventHealth.com
- Recruiting
Orlando Health Orlando Regional Medical Center
Orlando, Florida, 32806
Justin Zumsteg, MD, 321-843-5851, Justin.Zumsteg@orlandohealth.com
Carlis Rodriguez-Saavedra, 321-841-3631, Carlis.RodriguezSaavedra@orlandohealth.com
- Recruiting
University of Pennsylvania, Department of Orthopaedic Surgery
Philadelphia, Pennsylvania, 19104
Ines C Lin, MD, 215-662-7300, ines.lin@uphs.upenn.edu
Annamarie D. Horan, MPA, PhD, 215-847-0132, horana@pennmedicine.upenn.edu
- Recruiting
Allegheny Health Network
Pittsburgh, Pennsylvania, 15212
Steven Regal, MD, 877-660-6777, Steven.REGAL@ahn.org
Mary Fetter - Lead Clinical Research Coordinator, 412-359-8292, Mary.Fetter@ahn.org
- Recruiting
University of Utah Health
Salt Lake City, Utah, 84132
Mark A Mahan, MD, FAANS, 801-585-7917, mark.mahan@hsc.utah.edu
Kirstianna Lombardi, Lead Coordinator, 801-585-9821, kirstianna.lombardi@utah.edu
- Not yet recruiting
UCSF Health
San Francisco, California, 94158
Nicolas H Lee, MD MS, 415-206-8765, nicolas.lee@ucsf.edu
Tigist Belaye, MPA, CCRP, 415-205-5375, Tigist.Belaye@ucsf.edu
- Recruiting
Harborview Medical Center
Seattle, Washington, 98104
Yusha ( Katie) Liu, MD PhD, 206-744-3000, HMCnerve@uw.edu
Laura Hennessy, RN, 206-744-7723, hennessy@uw.edu
- Recruiting
Barnes-Jewish Hospital 1 Barnes Jewish Hospital Plaza St.
St Louis, Missouri, 63110
David M Brogan, MD, MSc, 314-747-2813, brogand@wustl.edu
Michelle Moore, Clinical Research Coordinator, 314-273-2403, michellemoore@wustl.edu
About this study
Official title: Phase 3, Multicenter, Randomized, Subject and Evaluator Blinded, Controlled Study Evaluating the Safety and Efficacy of NTX-001 Compared to Standard of Care (Neurorrhaphy) in the Treatment of Upper Extremity Transected Nerves Requiring Surgical Repair.
NTX-001 is a single use surgical product intended for use in conjunction with standard suture neurorrhaphy of severed nerves in patients between 18 and 80.
Read the detailed description
NTX-001 has been developed as a surgical product to be used in conjunction with standard suture neurorrhaphy of a severed nerve. Use of NTX-001 is intended to safely accelerate the often slow and diminished return of function in repaired nerves. It often takes months and/or years to determine if function will be restored. By that point, restoration is often incomplete and can result in lifelong motor and/or sensory deficits. By reconnecting (PEG-fusion) a substantial number of axons within a severed nerve, the degeneration-regeneration cycle and subsequent atrophy may be reduced or even prevented for those axons and their targets, respectively. NTX-001 (PEG-fusion) has the potential to avoid the consequences of protracted denervation of distal target tissues by eliminating the period of total denervation thus reducing the time to stable recovery and providing greater innervation to affected tissues.
- Being tested
- NTX-001 (PEG-Fusion)
- Keywords
- Transected Nerves, Requiring Surgical Repair, Upper Extremity
- Medical subject headings
- Peripheral Nerve Injuries
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NTX-001 (PEG-Fusion)Combination product
One time use surgical product, 3 solutions applied topically, in sequence, to the peripheral nerve repair site, in conjunction with standard suture neurorrhaphy.
| Study group | Role | What they receive |
|---|---|---|
| NTX-001 | Experimental | NTX-001 used during the surgical repair of an upper extremity peripheral nerve injury in conjunction with standard suture neurorrhaphy. Receives: Combination Product: NTX-001 (PEG-Fusion) |
| Standard Suture Neurorrhaphy | No intervention | Standard of Care |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean Michigan Hand Questionnaire (MHQ) Two Domain Score (ADL and Pain)
The subject will complete the MHQ questionnaire at Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, and 48. A measure of the mean of MHQ in the Two Domains, Activities of Daily Living and Pain Scores, at Week 24 in the NTX-001 group as compared to Standard of Care (SoC). In the ADL subdomain, a higher component score indicates better function. In the Pain subdomain, a higher component score indicates greater pain. A total MHQ score of 100 is considered the best functional score.
Measured: Screening Visit, Week 24
Safety - Columbia-Suicide Severity Rating Scale
The Columbia-Suicide Severity Rating Scale (C-SSRS) is a suicide risk assessment tool. The C-SSRS tool asks; whether and when the subject has had a thought about suicide (ideation); what actions they might have taken and what they did to prepare for suicide; whether and when they attempted suicide or began a suicide attempt that was either interrupted by another person or stopped of their own volition. The answers identify whether someone is at risk for suicide, assessing the severity and immediacy of that risk, and gauging the level of support that the person needs. The first assessment is done by study staff at screening. Subsequent assessments will be completed by the subject at Weeks 4, 12, and 48. A score of 0 indicates no risk, 1-2 indicates low risk, and 3+ indicates moderate to high risk.
Measured: Screening Visit, Weeks 4, 12, and 48
Secondary outcomes (13)
Intraoperative CheckPoint® Stimulation.
A CheckPoint® Stimulator will be used intra-operatively to detect immediate reconnection of severed peripheral nerves (axons) in mixed-motor nerves only. The measures include in response of direct nerve stimulation, proximally and distally to suture site.
Measured: In Operating Room
MHQ Total Score
The MHQ quantifies different impairments between the subjects in uninjured and involved upper extremities. A general survey of hand function includes twenty-five items for the right and the left hand, as well as questions for both hands. Questions regarding function specifically refer to the impact of the involved hand and/or wrist on the activity which presumably takes all joints of the upper extremity into account. The overall questionnaire is scored from 0 to 100, with 100 being the optimal score.
Measured: Screening Visit; Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, and 48
Time to Return to Function
Achievement of seventy-five (75)% function in the combined ADL and pain MHQ domain scores. The Activities of Daily Living component evaluates the ability to perform specific tasks using either hand or both hands together. The Pain subdomain addresses the frequency and intensity of pain in both the right and left hands/wrists, along with its impact on sleep and daily activities, and the emotional distress it causes. The overall questionnaire is scored from 0 to 100, with 100 being the optimal score.
Measured: Screening Visit, Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, and 48.
Change in NPRS
The NPRS is used to assess for pain and to determine pain intensity. The NPRS is an 11-point scale scored from 0-10: 1) "0" = no pain 2) "10" = the most intense pain imaginable. The average of the 3 ratings is used to represent the subject's level of pain over the previous 24 hours.
Measured: Screening Visit, Weeks 2, 4, 6, 8, 10, 12,16, 20, 24, 30, 36, 42, and 48
Semmes Weinstein Monofilament Test (SWMT)
SWMT provides information on protective sensation, the rigorous system can detect relatively minor differences in sensory function, and changes will occur early in nerve injury. The assessment tool consists of a set of monofilaments that vary in thickness and diameter, the gradient forces of these monofilaments that subjects\' can feel, range from 0.086 gm to 0.448gm. The normal value in the hand is in the range of the green filament (1.65 to 2.83 mN).
Measured: Weeks 2, 4, 8, 12, 24, 36, 48.
MHQ Two Domain Score
The Activities of Daily Living component evaluates the ability to perform specific tasks using either hand or both hands together. The Pain subdomain addresses the frequency and intensity of pain in both the right and left hands/wrists, along with its impact on sleep and daily activities, and the emotional distress it causes. The raw scale score for each of the 6 scales is the sum of the responses of each scale item. The raw score is converted to a score range from 0 to 100. 100 being the best.
Measured: Screening Visit; Weeks 2, 4, 6, 8, 10, 12, 16, 20, 30, 36, 42, 48
Change from Week 2 in MHQ Two Domain Score
The Activities of Daily Living component evaluates the ability to perform specific tasks using either hand or both hands together. The Pain subdomain addresses the frequency and intensity of pain in both the right and left hands/wrists, along with its impact on sleep and daily activities, and the emotional distress it causes. The raw scale score for each of the 6 scales is the sum of the responses of each scale item. The raw score is converted to a score range from 0 to 100. 100 being the best.
Measured: Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, and 48.
Medical Research Council Classification (MRCC) Sensory Score
The scale is commonly used including 2 Point Discrimination for grading the sensory outcome after peripheral nerve surgery. This scale is categorized into S0-S4: S0 is the absence of sensibility; S1 is the recovery of deep cutaneous pain; S2 is the return of superficial cutaneous pain and some degree of tactile sensibility; S3 is the return of superficial cutaneous pain and tactile sensibility without over response; and S4 is the complete recovery.
Measured: Weeks 2, 4, 8, 12, 24, 36, and 48.
Medical Research Council Classification (MRCC) Motor Score
This assessment is conducted on mixed motor nerve injuries only. Strength can best be assessed by isolating an individual muscle group and comparing power with that of the subject. It can be conducted to assess larger muscles or muscle groups as well as intrinsic muscles of the hand. Measuring the difference between the affected limb and the contralateral limb. 0/5 is no muscle activation whatsoever; 1/5 is muscle activation without limb movement; 2/5 implies that the limb can be moved only when gravity is taken out of the equation; 3/5 means that the subject can overcome gravity but not resistance;• 4/5 (or 4+ or 4-) implies weakness with enough strength to overcome varying degrees of physical resistance; 5/5 is full strength.
Measured: Weeks 2, 4, 8, 12, 24, 36, 48
Change from Baseline (W2) in Numeric Pain Rating Scale (NPRS)
The NPRS is used to assess for pain and to determine pain intensity. The NPRS is an 11-point scale scored from 0-10: 1) "0" = no pain 2) "10" = the most intense pain imaginable. The average of the 3 ratings is used to represent the subject's level of pain over the previous 24 hours.
Measured: Weeks 2, 24.
Patient Global Impression of Change Score
This scale evaluates all aspects of patients; health and assesses if there has been an improvement or decline in clinical status. PGIC is a 7-point scale depicting a subjects rating of overall improvement. The subject rates their change as "very much improved," "much improved," "minimally improved," "no change," "minimally worse," "much worse," or "very much worse."
Measured: Weeks 2, 4, 6, 8, 10, 12, 16, 20, 30, 36, 42, and 48
Change in Total MHQ Score
The MHQ quantifies different impairments between the subjects uninjured and involved upper extremities. It was designed as a general survey of hand function and includes twenty-five items for the right and the left hand, as well as questions for both hands. Furthermore, questions regarding function specifically refer to the impact of the involved hand and/or wrist on the activity which presumably takes all joints of the upper extremity into account. The overall questionnaire is scored from 0 to 100, with 100 being the optimal score.
Measured: Screening Visit; Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, and 48.
Change from Baseline in Patient Global Impression of Severity Score (PGIS)
The PGIS is a single question asking the subject to rate the severity of the injury from the last visit. PGIS is a scale depicting a subject's rating of overall severity. The subject scores their perception of severity as "none," "mild," "moderate," "severe," or "very severe."
Measured: Screening Visit; Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42 and 48.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Sep 2024
- Study start10 Feb 2025
- Primary completion31 Mar 2027 (estimated)
- Study completion30 Apr 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Peripheral Nerve Injury Upper LimbStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Treatment vs. Standard of Care
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 98 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Neuraptive Therapeutics Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Seth Schulman, MD, Study director, Neuraptive Therapeutics Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06616025
- Sponsor's protocol ID
- NTx24301
- Status last verified
- May 2026
- First submitted
- 24 Sep 2024
- Last updated
- 6 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 6 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase 3, Multicenter, Randomized, Subject and Evaluator Blinded, Controlled Study Evaluating the Safety and Efficacy of NTX-001 Compared to Standard of Care (Neurorrhaphy) in the Treatment of Upper Extremity Transected Nerves Requiring Surgical Repair.
- ClinicalTrials.gov ID
- NCT06616025
- Acronym / sponsor ID
- NTx24301
- Keywords
- Transected Nerves, Requiring Surgical Repair, Upper Extremity
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 98 participants (estimated)
- Lead sponsor
- Neuraptive Therapeutics Inc.Industry (pharma, biotech, devices)
- Study start
- 10 Feb 2025 (actual)
- Primary completion
- 31 Mar 2027 (estimated)
- Study completion
- 30 Apr 2027 (estimated)
- First posted
- 27 Sep 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
NTX-001 is a single use surgical product intended for use in conjunction with standard suture neurorrhaphy of severed nerves in patients between 18 and 80.
Detailed description
NTX-001 has been developed as a surgical product to be used in conjunction with standard suture neurorrhaphy of a severed nerve. Use of NTX-001 is intended to safely accelerate the often slow and diminished return of function in repaired nerves. It often takes months and/or years to determine if function will be restored. By that point, restoration is often incomplete and can result in lifelong motor and/or sensory deficits. By reconnecting (PEG-fusion) a substantial number of axons within a severed nerve, the degeneration-regeneration cycle and subsequent atrophy may be reduced or even prevented for those axons and their targets, respectively. NTX-001 (PEG-fusion) has the potential to avoid the consequences of protracted denervation of distal target tissues by eliminating the period of total denervation thus reducing the time to stable recovery and providing greater innervation to affected tissues.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, outcomes assessor)
- Number of arms
- 2
- Model description
- Treatment vs. Standard of Care
| Arm | Type | Receives |
|---|---|---|
| NTX-001 | Experimental | Combination Product: NTX-001 (PEG-Fusion)NTX-001 used during the surgical repair of an upper extremity peripheral nerve injury in conjunction with standard suture neurorrhaphy. |
| Standard Suture Neurorrhaphy | No intervention | –Standard of Care |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- The subject has voluntarily agreed to participate in this study and has signed an Institutional Review Board (IRB) approved informed consent form.
- The subject is between eighteen (18) and eighty (80) years of age.
- The subject has clinical evidence of a Sunderland's 4th degree (Class II) or 5th degree (Class III) nerve transection(s) that has resulted in upper extremity nerve impairment that requires surgical treatment.
Key exclusion criteria (9 listed)
- Subjects whose nerve repair will occur greater than 48 hours after nerve transection.
- Subjects requiring nerve repair involving an autograft, allograft or conduit(s).
- Subjects with multiple transected nerve injuries are allowed into the study only if all injuries are amenable to direct repair.
- Subjects who, in the judgement of the investigator, are not likely to demonstrate meaningful recovery within a reasonable time frame during follow up due to significant muscle atrophy or other morbidity.
- The subject's injury is a result of a suicide attempt or self- harm.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NTX-001 (PEG-Fusion)One time use surgical product, 3 solutions applied topically, in sequence, to the peripheral nerve repair site, in conjunction with standard suture neurorrhaphy. | Combination product | NTX-001 |
Primary outcome
Mean Michigan Hand Questionnaire (MHQ) Two Domain Score (ADL and Pain)
Time frame: Screening Visit, Week 24
The subject will complete the MHQ questionnaire at Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, and 48. A measure of the mean of MHQ in the Two Domains, Activities of Daily Living and Pain Scores, at Week 24 in the NTX-001 group as compared to Standard of Care (SoC). In the ADL subdomain, a higher component score indicates better function. In the Pain subdomain, a higher component score indicates greater pain. A total MHQ score of 100 is considered the best functional score.
Safety - Columbia-Suicide Severity Rating Scale
Time frame: Screening Visit, Weeks 4, 12, and 48
The Columbia-Suicide Severity Rating Scale (C-SSRS) is a suicide risk assessment tool. The C-SSRS tool asks; whether and when the subject has had a thought about suicide (ideation); what actions they might have taken and what they did to prepare for suicide; whether and when they attempted suicide or began a suicide attempt that was either interrupted by another person or stopped of their own volition. The answers identify whether someone is at risk for suicide, assessing the severity and immediacy of that risk, and gauging the level of support that the person needs. The first assessment is done by study staff at screening. Subsequent assessments will be completed by the subject at Weeks 4, 12, and 48. A score of 0 indicates no risk, 1-2 indicates low risk, and 3+ indicates moderate to high risk.
13 secondary outcomes
Intraoperative CheckPoint® Stimulation.
Time frame: In Operating Room
MHQ Total Score
Time frame: Screening Visit; Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, and 48
Time to Return to Function
Time frame: Screening Visit, Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, and 48.
Change in NPRS
Time frame: Screening Visit, Weeks 2, 4, 6, 8, 10, 12,16, 20, 24, 30, 36, 42, and 48
Semmes Weinstein Monofilament Test (SWMT)
Time frame: Weeks 2, 4, 8, 12, 24, 36, 48.
MHQ Two Domain Score
Time frame: Screening Visit; Weeks 2, 4, 6, 8, 10, 12, 16, 20, 30, 36, 42, 48
Change from Week 2 in MHQ Two Domain Score
Time frame: Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, and 48.
Medical Research Council Classification (MRCC) Sensory Score
Time frame: Weeks 2, 4, 8, 12, 24, 36, and 48.
Medical Research Council Classification (MRCC) Motor Score
Time frame: Weeks 2, 4, 8, 12, 24, 36, 48
Change from Baseline (W2) in Numeric Pain Rating Scale (NPRS)
Time frame: Weeks 2, 24.
Patient Global Impression of Change Score
Time frame: Weeks 2, 4, 6, 8, 10, 12, 16, 20, 30, 36, 42, and 48
Change in Total MHQ Score
Time frame: Screening Visit; Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, and 48.
Change from Baseline in Patient Global Impression of Severity Score (PGIS)
Time frame: Screening Visit; Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42 and 48.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Oct 2026.
- Sponsor WebsiteLink provided by the sponsor.
Related trials for Peripheral Nerve Injury Upper Limb
Recruiting
Comparison of Kinesio Taping Techniques in Ulnar Nerve Entrapment
Ulnar Nerve Entrapment, Cubital Tunnel Syndrome
RecruitingPhase 4
Study Comparing Avance Nerve Graft and Autograft for Functional Recovery Following Mixed and Motor Peripheral Nerve Reconstruction
Peripheral Nerve Injury, Peripheral Nerve Discontinuity
Recruiting
Effects of Peripheral Repetitive Peripheral Magnetic Stimulation on Individuals With Elbow or Wrist Chronic Pain
Tennis Elbow Syndrome, Golfer's Elbow
Not yet recruiting
Understanding Patient Preferences When Deciding on a Voluntary Musculoskeletal Test
Non-traumatic Musculoskeletal Conditions, Carpal Tunnel Syndrome (CTS)
Active, not recruitingPhase 4
Brachial Plexus Nerve Block Versus Haematoma Block for Closed Reduction of Distal Radius Fracture in Adults - The BLOCK Trial. A Multicentre Randomised Controlled Trial.
Distal Radius Fractures, Fracture Dislocation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Seth Schulman, MD study director
Neuraptive Therapeutics Inc.
25 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing NTX-001 (PEG-Fusion) in people with Peripheral Nerve Injury Upper Limb and Peripheral Nerve Injury (PNI), run by Neuraptive Therapeutics Inc. at 25 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 25 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Seth Schulman, MD (215-206-9504, seth.schulman@neuraptive.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean Michigan Hand Questionnaire (MHQ) Two Domain Score (ADL and Pain) (time frame: Screening Visit, Week 24). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Oct 2026.